Voyageur Pharmaceuticals (VM.V) Stock Analysis & Winston Score
Voyageur Pharmaceuticals is a small Canadian company focused on developing and commercializing specialty pharmaceutical products. Its main focus is on barium sulfate contrast agents — chemicals used in medical imaging scans to help doctors see inside the body more clearly. The company aims to supply these products to hospitals and medical imaging clinics, primarily in Canada. Voyageur generates revenue through product sales, but it is currently a very early-stage company and spends far more money than it earns, as shown by its deeply negative margins. It operates mainly in Canada and has a very small market presence. The company's potential edge lies in owning domestic Canadian production of barium sulfate, which could reduce reliance on foreign suppliers — but the main risk is that it has not yet proven it can scale production, generate consistent revenue, or reach profitability, making it a highly speculative investment at this stage.
Winston Score: 16/100 — Weak
Weak fundamentals across most pillars.
- Quality: Weak (1/30)
- Growth: Weak (1/20)
- Cash Flow: Weak (0/10)
- Stability: Good (5/10)
- Valuation: Data not available (0/10)
- Ownership: Good (8/15)
Key Facts
Price: 0.14 CAD
Market Cap: 24M CAD
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Exchange: Toronto Stock Exchange Ventures
